Objective: Although reduction of vasomotor symptoms (VMS; hot flashes and night sweats) has been reported in postmenopausal women who used isoflavones, a clear dose response has not been shown, has largely not been reported for perimenopausal women, and has largely only been reported for reducing prevalent VMS, not preventing newly developing VMS. We analyzed longitudinal data from the Study of Women's Health Across the Nation for the relation of dietary phytoestrogen and fiber intake to incident VMS in this multiracial/ethnic cohort.
T he North American Menopause Society recently issued a position statement on isoflavones for menopausal health 1 in which they summarized the results of 14 randomized placebo-controlled trials of soy isoflavone supplements for vasomotor symptoms (VMS). Lower rates of VMS were reported in most studies (including randomized trials) of postmenopausal women who used soy isoflavone supplements. 2<10 However, the effect has not shown a clear dose response, has largely not been reported for perimenopausal women (as noted in the position statement) even though perimenopausal women have rates of VMS at least as high as those of postmenopausal women, 11 has only involved supplements and not dietary isoflavones, and has largely only been related to reducing VMS in women who have them, rather than preventing newly developing incident VMS.
Phytoestrogens (Bplant estrogens[) are heterocyclic phenols found in many plant foods. Three major categories have been established within the general class of phytoestrogens: isoflavones (eg, daidzein and genistein), coumestans (eg, coumestrol), and lignans (eg, secoisolariciresinol and matairesinol). Isoflavones, lignans, and coumestrol bind to > and A estrogen receptors and are predominantly agonists. 12<14 However, the ultimate effects of phytoestrogens on the estrogen pathway are likely to be determined by a variety of factors, including the following: their relative affinity for > and A estrogen receptors and effects on the conformation of these receptors; their agonist or antagonist properties related to their concentrations and to circulating levels of estradiol; and the different phytoestrogens (isoflavones, lignans, and coumestrol) that each modify the metabolism and bioavailability of endogenous estrogen by mechanisms that either increase or decrease such bioavailability. 11<18 In one early trial, postmenopausal women who received soy supplements (containing isoflavones) or wheat flour (containing enterolactones) had a statistically significant reduction in VMS (40% in the soy group and 25% in the wheat group), although the rates of decline did not differ significantly (partly because of the small sample size). 2 Most, 3<6 but not all, 19 subsequent randomized, double-blind, controlled clinical trials of soy or soy isoflavones for VMS have observed similar reductions in VMS. In contrast, trials that included perimenopausal women have not observed lower rates of VMS in relation to greater phytoestrogen administration. 20<23 The apparent menopause stageYspecific results suggest that the effects of dietary phytoestrogens vary according to the menopausal transition (MT) stage, perhaps reflecting differences in circulating endogenous estrogen levels. However, many other aspects of the design and methods of the above-mentioned trials may also have produced inconsistent results. Several types, doses, and formulations of phytoestrogens have been used. In addition, sample sizes in trials have been small to moderate, ranging from 39 4 to 177 5, 20 ; thus, limited statistical power to detect effects may also have led to inconsistent outcomes. Most importantly, however, these trials have focused on women who already have VMS, and relatively few studies have examined the relation of phytoestrogen intake to developing incident VMS. Furthermore, studies have not examined whether the effects of phytoestrogens on VMS differ by race/ethnicity, perhaps reflecting underlying differences in metabolism, which is another possible source of differing results.
In addition, urinary excretion of phytoestrogens and the concentration of plasma sex hormoneYbinding globulin have been positively associated with dietary intake of fiber, which has been inversely related to circulating levels of estradiol. 24<34 Few studies have investigated the relation of dietary fiber to VMS reporting, but one cross-sectional study of women with prior early-stage breast cancer showed a protective effect. 35 Furthermore, fiber may be a proxy for lignan intake. If the measurement of fiber is more accurate than the measurement of lignans, the protective association between fiber and VMS reporting may be stronger than that for lignans.
Evidence from these small-to medium-sized studies suggests that soy or soy isoflavones suppress VMS in postmenopausal (but not in perimenopausal) women. The effects of other classes of phytoestrogens remain uncertain, and their effects on the development of new VMSVrather than on the reduction of existing VMSVhave not been well studied. We undertook several analyses to build upon prior work by testing the relation between dietary phytoestrogens and development of incident VMS longitudinally, considering the relations in each stage of the MT. As outlined above, the effects of phytoestrogens on VMS would be expected to differ according to the specific phytoestrogen and MT stageVa theory that we tested in the multi-racial/ethnic longitudinal cohort of the Study of Women's Health Across the Nation (SWAN). We improved the phytonutrient database used to determine dietary intake in SWAN 36 to investigate whether other classes of phytoestrogensVin addition to isoflavones, particularly lignans and dietary fiberVwere related to the incident reporting of VMS in SWAN. These analyses examined the longitudinal relations between each of the three main classes of phytoestrogens and dietary fiber (exposures) and incident VMS (outcome).
Specifically, we undertook analyses of SWAN's annual data and dietary assessment to test the following hypotheses: (1) higher dietary intake of total isoflavones, total lignans, coumestrol, and/or dietary fiber would be associated with lower rates of reporting newly occurring VMS longitudinally; and (2) the relation of each class of phytoestrogens and dietary fiber to incident VMS would vary by MT stage, with stronger benefit observed in postmenopause.
METHODS

Study participants
Eligibility for the cohort at baseline included the following criteria: aged 42 to 52 years, intact uterus and at least one ovary, not currently using exogenous hormones affecting ovarian function, a menstrual period in the past 3 months, and self-identification with each site's designated racial/ ethnic groups. Each site screened one minority population (African Americans in Pittsburgh, Boston, Detroit area, and Chicago; Japanese in Los Angeles; Chinese in the Oakland, CA, area; and Hispanics in New Jersey) and a white population, using community-based sampling. 37 Each site recruited approximately 450 eligible participants (total of 3,302). The Institutional Review Boards at all sites approved the protocol, and all participants provided a signed written informed consent form.
The following exclusions were applied to create the substudy cohort. The New Jersey SWAN site was omitted (n = 432) because of high attrition (on SWAN follow-up visit 5, retention was 18% for white women and 45% for Hispanic women) and because that site did not collect any dietary data at follow-up visit 9. The following diet-based exclusions were applied to the six participating SWAN sites at baseline: participant did not have dietary assessment (n = 11), reported intake of less than 4 or more than 17 solid foods per day (n = 130), skipped more than 10 food items (n = 1), or had a calculated daily energy intake of less than 500 kcal or more than 5,000 kcal (n = 7). If any of these diet-based exclusionary criteria was met at later visits, dietary variables were set to missing for those visits. Thus, the SWAN substudy cohort included 2,721 women at baseline, 1,905 (70.0%) at follow-up visit 5, and 1,673 (61.5%) in follow-up visit 9, based on the availability of acceptable dietary data.
In addition, the following exclusions were applied to the current analysis of phytoestrogens and VMS: women who had VMS at baseline (to enable evaluation of dietary intake with incident VMS [n = 1,070], leaving 1,651 women without VMS at baseline); self-reported hormone use or unknown current menopause status because of hormone use (n = 3,749 of 29,931 observations); and observations concurrent with pregnancy (n = 6). Of the 1,651 women without VMS at baseline, 1,081 (65.5%) completed annual visit 5, and 1,184 (71.7%) completed visit 9; baseline and visits 5 and 9 were the only visits when dietary data were collected. Of the 1,081, 942 (87%) provided dietary data at visit 5, and 954 of the 1,184 (80.6%) provided dietary data at visit 9. Women who did not complete the food frequency questionnaire were more likely (differed significantly and by 910%) than those who did to report premenstrual symptoms and to be white or black (non-Asian), early perimenopausal at baseline, less educated, previously married, in a lower income household, current smokers, and more exposed passively to smoke (data not shown). We adjusted for these characteristics in multivariate analyses to reduce possible nonresponse bias. 38 
Data collection
The baseline and annual clinic visits included an in-person interview, self-administered questionnaires, and measurement of weight, height (using calibrated scales and a stadiometer), waist circumference, and hip circumference. Dietary data were obtained using a modified 1995 Block Food Frequency Questionnaire 39, 40 with 103 core food items, based on the responses of African Americans and whites to the Second National Health and Nutrition Examination Survey. 39, 41 Foods for the Hispanic, Chinese, and Japanese versions, identified from the Hispanic Health and Nutrition Examination Survey 42 and focus groups, were also added. Frequently consumed sources of dietary phytoestrogens were also included 43 (tofu, soy milk, soy sauce, and meat substitutes made from soy). Common protocols, manual of operations, training, and staff certification for administering the protocols were used at all sites. All data collection instruments were translated into Cantonese, Japanese, and Spanish and backtranslated; discrepancies in translation were resolved by two translators.
Independent variables
For dietary phytoestrogen exposure variables, we used a new database that was developed as described by Huang et al. 36 In brief, the original phytoestrogen database for use in SWAN was constructed in 1994 and contained information about two isoflavones (daidzein and genistein) and coumestrol. Huang et al. 36 expanded this original database by covering the period between 1994 and 2008, which allowed computation of nutrient values for: four isoflavones (Kg/d) as the sum of formononetin, daidzein, genistein, and glycitein; coumestrol (Kg/d) and four lignans (Kg/d) as the sum of matairesinol, lariciresinol, pinoresinol, and secoisolariciresinol, in addition to dietary fiber (mg/d) and total phytoestrogens (Kg/d). These were assessed from the food frequency questionnaires completed by participants at baseline and at annual visits 5 and 9. We interpolated values for visits 1 to 4, 6 to 8, and 10 and for women who were missing dietary data on visit 5 or 9. 44 We also reran analyses using only visits at which the food frequency questionnaire was conducted (baseline and followup visits 5 and 9) and using the last observation carried forward method rather than model-based interpolation (results from all three methods were similar; thus, only the models using interpolation are presented). Dietary variables were linearly regressed over follow-up time (number of years since SWAN baseline visit). This longitudinal linear regression model was used to output each participant's random intercept and slope, as well as the fixed slope and intercept for each of the dietary variables. We produced Loess curves to assess linearity as the first step in interpolation. For each dietary variable, the fixed and random intercepts were summed, and the fixed and random slopes were summed. Time was multiplied by each summed slope and added to the summed intercept. Finally, each original dietary variable value was linearly regressed with its interpolated value to assess the quality of the interpolation; a slope close to 1.0 and an intercept close to 0 would signal that the interpolation was robust. The correlation between the original values and the interpolated values was also computed, with higher correlations indicating better interpolation.
Outcome variable
The frequency of VMS (hot flashes and/or night sweats)V0, 1 to 5 days, or 6 days or more in the prior 2 weeksVwas asked at each annual visit. We excluded women who reported any VMS at baseline (leaving 1,651 without baseline VMS) to examine the relations of phytoestrogen intake to newly developing VMS during follow-up; this allowed for a better assessment of the temporal ordering of VMS and phytoestrogen intake. For these analyses, the annual reports of VMS were categorized as a three-category ordinal outcome variable for the multinomial logistic regressions described below: none in the past 2 weeks, 1 to 5 days in the past 2 weeks, or 6 days or more in the past 2 weeks.
Covariates
Time-invariant covariates measured at baseline included variables previously shown to be related to VMS 11 : educational level (less than high school, high school, some college, college, or postbaccalaureate degree); race/ethnicity (selfdesignated white, African American, Japanese, or Chinese); anxiety score (as a binary variable, using a cutoff of 94 or e4 for a summed score of the numbers of days in the past 2 weeks [0 = no days to 4 = every day] reporting irritability or grouchiness, feeling tense or nervous, heart pounding or racing, and feeling fearful for no reason); depressive symptom score (score Q16 on a 20-item scale on the extent to which each item was experienced in the previous week) 45 ; history of premenstrual symptoms; symptom sensitivity on visit 1 (using quartiles of a summed score of the degree of awareness of loud noise, hot or cold, hunger, pain, and things happening in one's body; 1 = not at all true to 5 = extremely true) 46 ; SWAN study site; marital status; overall health score; passive smoke exposure(person hours/week) 47 ; and quartiles of physical activity score. 48, 49 In our final model, only site, physical activity, education, marital status, number of premenstrual symptoms, depressive symptom score, and symptom sensitivity were retained.
Annually measured time-varying covariates included the following: age (years); MT stage (premenopausal, indicating a menstrual period in the prior 3 months and no change in menstrual regularity in the prior year; early perimenopausal, indicating menses in the prior 3 months and changes in regularity in the prior year; late perimenopausal, indicating no menses in the prior 3 months but menses in the prior 11 months; postmenopausal, indicating Q12 mo of amenorrhea); body mass index (BMI; [weight in kilograms/(height in meters) 2 ]; categories G25, 25-29.9, and Q30); total kilocalories of energy intake and fiber from the food frequency questionnaires at baseline and at annual visits 5 and 9 and interpolated for the intervening years; perceived stress (a summed scale asking how often during the prior 2 weeks four aspects of stress were experienced; 1 = never to 5 = very often) 50 ; annual serum estradiol level; annual sex hormoneYbinding globulin level; day of menstrual cycle of the blood draw; current smoking 51 ; alcohol use in the past 24 hours; number of life events; and social support, 52 with visit 9 interpolated from the previous visit. The final model only retained annual serum estradiol level, day of cycle, age, menopause status, BMI categories, and perceived stress.
Data analyses
Analyses were restricted to women who did not report VMS at baseline (n = 1,651) so that the relation of dietary phytoestrogen to incident VMS during follow-up could be assessed. Dietary variables were natural log transformed to handle skewness. To allow for nonlinear associations with VMS frequency and to facilitate assessment of the interaction of dietary intakes with menopause status, we categorized each of the three main classes of phytoestrogens and dietary fiber according to sample quartiles, using the top quartile as the reference category in analyses. In addition, we tested for linear associations (trend) by treating the quartiles as a continuous variable (quartiles 1 through 4).
The distributions of phytoestrogen classes and dietary fiber differed across the four racial/ethnic groups. The distribution of isoflavones was strongly bimodal, with two almost nonoverlapping peaks; the Chinese and Japanese (hereafter called Asian) women had vastly higher isoflavone intakes compared with the African-American and white (hereafter called non-Asian) women. Thus, we created separate Asian and non-Asian quartiles for all three classes of phytoestrogens and fiber and stratified all analyses by Asian/non-Asian ethnicity.
Using multinomial logistic regression with generalized estimating equations 53, 54 to account for within-woman correlation, we modeled odds ratios (ORs) and 95% CIs for inci-dent VMS at each follow-up visit as a function of the primary predictors (isoflavones, lignans, fiber, and coumestrol) and time-varying and time-invariant covariates, and we modeled with and without time-varying estradiol to determine if this was a potential mechanism of action. We used P G 0.2 to enter covariates into the regression models and retained those with P G 0.05. We used multinomial rather than ordinal logistic regression, despite the inherent ordering of the VMS outcome, because preliminary analyses suggested that the former model is more flexible and fits the data better than the latter model, which assumes proportional odds for cumulative logits.
To ensure that our primary exposures were measured before the VMS outcome, we lagged the time-varying dietary variables (ie, taken from dietary data for the visit before the VMS outcomes); for example, visit 5 VMS were modeled as a function of baseline dietary variables, and visit 4 VMS were modeled as a function of baseline dietary variables (or, equivalently, change between baseline and visit 4). Each dietary variable had its own model to avoid multicollinearity. We also tested the interaction between menopause status and phytoestrogen and dietary fiber intake exposures. We also conducted exploratory analyses using structural equation modeling to ensure that reverse causation did not occur (ie, that women with more frequent VMS were increasing their intake of isoflavones to treat their symptoms).
RESULTS
Because we restricted our analyses to women who did not report VMS at baseline so that we could see the relation of isoflavones and other phytoestrogens to the development of VMS during follow-up, we first compared the baseline characteristics of women who did (n = 1,070) and did not (n = 1,651) report VMS at baseline (Table 1) . Women with the following characteristics were significantly more likely to report VMS at baseline: white or black, early perimenopausal, less educated, unemployed, lower annual household income, blood not collected on days 2 to 5 (related to being perimenopausal), elevated depressive symptom score, poorer self-assessed health, more premenstrual symptoms, smoker, passive exposure to cigarette smoke, elevated anxiety score, older, higher parity, higher BMI, higher symptom sensitivity score, higher stress score, higher life events score, lower phytoestrogen intake, and higher energy intake.
Findings for African Americans and whites (non-Asians) Isoflavones
In adjusted models (Table 2A) , no baseline or lagged isoflavone quartiles were significantly related to incident VMS of any frequency, except that the lowest quartile of lagged isoflavone intake had a significantly reduced OR for 1 to 5 days of VMS in the prior 2 weeks (OR, 0.76; 95% CI, 0.61-0.95; P = 0.016), and the P value for trend for the quartiles was statistically significant (P = 0.018) for 1 to 5 days of VMS. When we interpolated the isoflavone values using the approach of last time point followed forward, the magnitude and direction of ORs were largely similar, but the relation of lagged isoflavone intake to 1 to 5 days of VMS and the overall comparison of groups were no longer significant (data not shown).
Coumestrol
In adjusted models (Table 2B) , lagged coumestrol intake among non-Asians was not significantly related to incident VMS of any frequency. However, the three lowest quartiles of baseline coumestrol had significantly reduced adjusted ORs compared with the highest quartile for 1 to 5 days of VMS in the prior 2 weeks (ORs ranged from 0.72 for the lowest quartile to 0.80 for the third quartile) with the P value for trend of 0.010, reflecting decreasing ORs with decreasing quartiles of baseline intake. Only the second quartile of baseline coumestrol had a significantly reduced OR compared with the highest quartile for 6 days or more of VMS in the prior 2 weeks (OR, 0.69; 95% CI, 0.50-0.95; P = 0.021), and no significant trends were observed for the quartiles. Adjusted for time-varying estradiol, day of cycle on which blood was drawn, age quartiles, menopause status, perceived stress, and body mass index, and time-invariant site, baseline physical activity, education, baseline marital status, baseline number of premenstrual symptoms, baseline symptom sensitivity quartiles, and baseline Center for Epidemiologic Studies Depression Scale score.
Lignans
In adjusted models (Table 2C) , both lagged and baseline lignan intakes were not significantly related to any incident VMS in non-Asian women. However, the P value for trend was statistically significant for lagged lignan intake related to 6 days or more of VMS in the prior 2 weeks, reflecting increasing ORs with decreasing quartiles of intake.
Fiber
In adjusted models, lagged fiber intake was not significantly associated with incident VMS of any frequency in non-Asian women (Table 2D ). The second and third quartiles of baseline fiber had significantly higher ORs compared with the highest quartile for 6 days or more of VMS in the prior 2 weeks (for the second quartile: OR, 1.56; 95% CI, 1.12-2.17; P = 0.009; for the third quartile: OR, 1.40; 95% CI, 1.02-1.91; P = 0.034), although the P value for trend was not statistically significant.
Findings for Chinese and Japanese women (Asians) Isoflavones
In adjusted models for Asian women (Table 3A) , neither lagged nor baseline isoflavone intakes were significantly related to incident VMS of any frequency.
Coumestrol
In adjusted models (Table 3B) , both lagged and baseline coumestrol intakes were not significantly related to incident VMS of any frequency in Asian women, except that the lowest quartile of lagged coumestrol intake had an increased adjusted OR, compared with the highest quartile, for 6 days or more of VMS in the prior 2 weeks (OR, 2.59; 95% CI, Adjusted for time-varying estradiol, day of cycle on which blood was drawn, age quartiles, menopause status, perceived stress, and body mass index, and time-invariant site, baseline physical activity, education, baseline marital status, baseline number of premenstrual symptoms, baseline symptom sensitivity quartiles, and baseline Center for Epidemiologic Studies Depression Scale score. 1.19-5.63), and the P value for trend was 0.052, reflecting increasing ORs for 6 days or more of VMS with decreasing intake of lagged coumestrol.
Lignans and fiber
Lagged lignan intake was not significantly related to any incident VMS in adjusted models for Asian women (Table  3C) , except for the third quartile, compared with the highest quartile, for VMS of 6 days or more (OR, 1.80; 95% CI, 1.01-3.22; P = 0.046). However, baseline lignan intake had a significantly reduced adjusted ORs for the third quartile compared with the highest quartile for 1 to 5 days of VMS in the prior 2 weeks (OR, 0.61; 95% CI, 0.39-0.94; P = 0.027) and showed a significant trend (P = 0.039) with increased ORs with increasing intake for 6 days or more of VMS in the prior 2 weeks (Table 3C ). When we interpolated values using the approach of last time point followed forward, the ORs for lignan intake related to 1 to 5 days of VMS all became greater than 1.0 and were significant for the second and third quartiles, and the overall comparison of groups became significant (data not shown). No significant adjusted associations were observed for lagged or baseline fiber intake among Asian women (Table 3D ), except that the second quartile of baseline fiber intake had a significantly increased adjusted OR compared with the highest quartile for 6 days or more of VMS in the prior 2 weeks (OR, 3.23; 95% CI, 1.46-7.16; P = 0.004) (Table 3D ).
Supplemental analyses
Because some of the few statistically significant findings were in directions opposite to what we expected, we estimated structural equation models to determine if the results were caused by reverse causation, and we observed no such indication (data not shown). We also examined the interactions of each type of phytoestrogen and fiber with menopause status in relation to incident VMS in Asians and non-Asians separately. Owing to small cell counts among Asians, we categorized time-varying phytoestrogens and fiber as above or below the median, rather than into quartiles. Only one statistically significant interaction (P G 0.05)Vfor high versus low isoflavones in Asians (P = 0.020 for interaction)Vwas identified. The pattern of effect modification by menopause status differed for 1 to 5 days of VMS versus none and for 6 days or more of VMS versus none, however, with the strongest benefit of high isoflavone consumption being observed during late perimenopause and postmenopause for 1 to 5 days of VMS but during premenopause for 6 days or more (data not shown). Given this discrepancy, as well as the lack of a main effect for isoflavones and the multiple statistical comparisons undertaken, these results may be attributable to chance. Similarly, the couple of changes in the findings noted above with interpolation of dietary intakes, using the last time followed forward method were probably because of chance, resulting from the large number of statistical comparisons made.
DISCUSSION
In our longitudinal analyses of a large, multiracial/ethnic cohort of midlife women who were followed for 10 years, no consistent significant patterns emerged from the relation of individual phytoestrogen categories (total isoflavones, coumestrol, or lignans) or fiber to incident VMS. Although some adjusted ORs were statistically significant, patterns were largely not monotonic for the amount of intake of each phytoestrogen or fiber in relation to the frequency of VMS. Thus, the few significant individual point estimates may well have been because of chance, given the many statistical comparisons that were made.
It is reasonable to compare our findings to trials that aimed to reduce VMS in women who already have them that have included perimenopausal women because, for at least half of the duration of follow-up in this study, most of our participants were not postmenopausal. Consistent with our findings, most such trials have not observed reductions in VMS in relation to higher phytoestrogen dose administrations. 20<23 Most, but not all, 19 trials to reduce VMS in postmenopausal women using phytoestrogen supplementation have found significant but relatively modest reductions, findings that are largely inconsistent with our findings. However, because these trials have focused on reducing VMS in women who already have them and thus have already undergone or are experiencing physiological changes that result in VMS, the effects of phytoestrogens may not be comparable to our study of incident VMS in women who did not have them at baseline.
Our study had several important strengths. First, it included some of the largest numbers of midlife women from four racial/ethnic groups that have been included in studies of the relation of phytoestrogen intake to VMS to date. Second, it included 10 years of longitudinal data points for VMS while our study participants underwent the MT, a time when the occurrence of such symptoms increases. 11 Third, it included an enhanced database of the dietary intake of phytoestrogens with updated estimates of such intake based on currently available food products. 36 Fourth, the estimated dietary intakes of phytoestrogen and fiber were made independently of any assessment of VMS reporting in study participants. Finally, the study was unique in its potentially important preventive implications because we only analyzed dietary phytoestrogen and fiber intakes in relation to incident VMS in women who did not report VMS at baseline.
However, the study also had a number of limitations that must be considered when interpreting the findings. First, the study was observational (not a randomized trial), so that other uncontrolled characteristics of women may have determined their phytoestrogen and fiber intake and may have also been related to their VMS reporting. Second, both dietary intake and VMS were self-reported (without validation), so that misclassification could have occurred in both exposures and outcome. Third, the proportion of women in our analytical baseline sample who completed the dietary and other questionnaires was 70% at visit 5 and 61.6% at visit 9, which could have introduced participation bias. Finally, despite the relatively large numbers of women studied in this cohort, the sample size became too small to evaluate effect modification by both race/ethnicity and menopause status, so that meaningful modifications may have not been detected as statistically significant.
CONCLUSIONS
We did not observe any consistent monotonic relations between categories of phytoestrogen or dietary fiber intake and incident VMS in our large, multi-racial/ethnic cohort of midlife women who were followed for 10 years through the MT. Although this observational cohort study was large, had a diverse study sample, and had high-quality dietary, outcome, and covariate data, for certainty about any effect of phytoestrogens or fiber on the prevention of VMS in midlife women who do not yet have them, we would need to undertake a large, randomized, placebo-controlled, double-masked trial that: (1) studied different categories and doses of phytoestrogens and fiber; (2) included sufficient numbers of women in different stages of the MT; (3) provided sufficiently long follow-up (on the order of several years to a decade); (4) was sufficiently powered to be able to determine if select subsets of women (probably based on genetically determined metabolism capabilities, such as being an equol producer) might benefit from increased intake of phytoestrogens and/or fiber; and (5) provided some validation or objective measures of VMS. Given that a high proportion of (indeed most) women develop VMS during the MT and that these are frequent 11 and disturbing to many women who are affected by them, 55 identifying whether a lifestyle modification (such as increased dietary phytoestrogen and/or fiber) might reduce the occurrence and/or frequency of VMS would provide important information to midlife women and their healthcare providers, although the findings of our longitudinal observational study suggest that such a reduction is likely to be small if it exists at all.
